Novartis Tafinlar + Mekinist demonstrates long-term, relapse-free survival benefit for high-risk, stage III melanoma patients in study published in NEJM
?|?Source:?Novartis International AG
- COMBI-AD is first trial to demonstrate 5-year relapse-free survival with targeted therapy as adjuvant treatment in high-risk patients with stage III BRAF-mutated melanoma1
- Adjuvant treatment with standard-of-care targeted therapy Tafinlar + Mekinist reduced the risk of relapse or death by 49% compared to placebo1
- Updated data show Tafinlar + Mekinist improved distant metastasis-free survival, a secondary endpoint1
- That has spread to other parts of the body (metastatic) or cannot be removed by surgery (unresectable), and
- That has a certain type of abnormal "BRAF" (V600E or V600K mutation-positive) gene
- That has spread to other parts of the body and you have no satisfactory treatment options, and
- That has a certain type of abnormal "BRAF" gene
# # #
Novartis Media Relations E-mail:?media.relations@novartis.comAnja von Treskow Novartis External Communications +41 79 392 8697 (mobile) anja.von_treskow@novartis.com Eric Althoff Novartis US External Communications +1 646 438 4335 eric.althoff@novartis.com | Dan Connelly Novartis Oncology Communications +1 862 210 0217 (direct) daniel.connelly@novartis.com |
Central | North America | ||
Samir Shah | +41 61 324 7944 | Sloan Simpson | +1 862 778 5052 |
Thomas Hungerbuehler Isabella Zinck | +41 61 324 8425 +41 61 324 7188 | ||